Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-small Cell Lung Cancer With STK11/LKB1 Mutation × daratumumab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 59 Recurrence 4 Immunoglobulin Light-chain Amyloidosis 3 Smoldering Multiple Myeloma 2 Neoplasms 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Triple Negative Breast Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Myeloid, Acute 1 Amyloidosis 1 Acute Kidney Injury 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05807048 2026-03-10

Daratumumab in STK11 Mutated NSCLC

NYU Langone Health

Phase 2 Completed

Non-small Cell Lung Cancer With STK11/LKB1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡